Researchers published a scalable dilution‑and‑delay (DnD) susceptibility assay that resolves low‑frequency and inducible antibiotic resistance phenotypes missed by standard tests. The Nature Communications study by Ma and Kim demonstrates high‑resolution, high‑throughput detection across bacterial strains, enabling earlier identification of resistance mechanisms that can compromise therapy. The DnD workflow leverages temporal resolution and automated dilution series to capture delayed growth and heteroresistance, features often overlooked in routine clinical microbiology. Authors argue the method could reshape surveillance, stewardship and diagnostic pipelines by reducing false‑negative resistance calls. Translating the assay into clinical labs will require validation in real‑world samples and integration with existing susceptibility platforms, but the technique offers a potential route to better inform antimicrobial selection and curb treatment failures.